NCT04046432View on ClinicalTrials.gov

Effects of Vigiis 101-LAB on a Healthy Populations' Gut Microflora, Peristalsis, Immunity, and Anti-oxidative Capacity

NACompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

March 27, 2017

Primary Completion Date

December 22, 2017

Study Completion Date

March 20, 2018

Conditions
Gastrointestinal Microbiome
Interventions
DIETARY_SUPPLEMENT

Vigiis 101-LAB

examined the effects of the Vigiis 101-LAB capsules I or II (5 or 10 billion CFU/day)

DIETARY_SUPPLEMENT

Placebo

Maltodextrin was used as a placebo.

Trial Locations (1)

104

Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei

All Listed Sponsors
collaborator

National Taiwan University Hospital

OTHER

collaborator

Chung Shan Medical University

OTHER

lead

SunWay Biotech Co., LTD.

INDUSTRY

NCT04046432 - Effects of Vigiis 101-LAB on a Healthy Populations' Gut Microflora, Peristalsis, Immunity, and Anti-oxidative Capacity | Biotech Hunter | Biotech Hunter